JPH11514015A - 胃腸管保護作用により炎症性腸疾病で治癒効果を有するフラボン及びフラバノン化合物 - Google Patents
胃腸管保護作用により炎症性腸疾病で治癒効果を有するフラボン及びフラバノン化合物Info
- Publication number
- JPH11514015A JPH11514015A JP10508712A JP50871298A JPH11514015A JP H11514015 A JPH11514015 A JP H11514015A JP 10508712 A JP10508712 A JP 10508712A JP 50871298 A JP50871298 A JP 50871298A JP H11514015 A JPH11514015 A JP H11514015A
- Authority
- JP
- Japan
- Prior art keywords
- hydroxy
- flavone
- hydrogen
- alkyloxy
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 flavanone compounds Chemical class 0.000 title claims abstract description 45
- 229930003944 flavone Natural products 0.000 title claims abstract description 28
- 235000011949 flavones Nutrition 0.000 title claims abstract description 28
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 title claims abstract description 24
- 229930003949 flavanone Natural products 0.000 title claims abstract description 24
- 235000011981 flavanones Nutrition 0.000 title claims abstract description 24
- 208000022559 Inflammatory bowel disease Diseases 0.000 title claims abstract description 13
- 230000000694 effects Effects 0.000 title description 25
- 210000001035 gastrointestinal tract Anatomy 0.000 title description 10
- 150000002213 flavones Chemical class 0.000 title description 6
- 150000002212 flavone derivatives Chemical class 0.000 claims abstract description 27
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims abstract description 25
- 238000004519 manufacturing process Methods 0.000 claims abstract description 25
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims abstract description 25
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 230000002496 gastric effect Effects 0.000 claims abstract description 18
- 150000001875 compounds Chemical class 0.000 claims description 53
- 229910052739 hydrogen Inorganic materials 0.000 claims description 31
- 239000001257 hydrogen Substances 0.000 claims description 31
- 125000003545 alkoxy group Chemical group 0.000 claims description 27
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 24
- 150000002431 hydrogen Chemical class 0.000 claims description 22
- 230000006378 damage Effects 0.000 claims description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- 125000006239 protecting group Chemical group 0.000 claims description 7
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 claims description 5
- ZWVHTXAYIKBMEE-UHFFFAOYSA-N 2-hydroxyacetophenone Chemical group OCC(=O)C1=CC=CC=C1 ZWVHTXAYIKBMEE-UHFFFAOYSA-N 0.000 claims description 4
- DQFBYFPFKXHELB-UHFFFAOYSA-N Chalcone Natural products C=1C=CC=CC=1C(=O)C=CC1=CC=CC=C1 DQFBYFPFKXHELB-UHFFFAOYSA-N 0.000 claims description 4
- 235000005513 chalcones Nutrition 0.000 claims description 4
- DQFBYFPFKXHELB-VAWYXSNFSA-N trans-chalcone Chemical compound C=1C=CC=CC=1C(=O)\C=C\C1=CC=CC=C1 DQFBYFPFKXHELB-VAWYXSNFSA-N 0.000 claims description 4
- 238000011282 treatment Methods 0.000 claims description 4
- 238000005575 aldol reaction Methods 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 150000001555 benzenes Chemical group 0.000 claims description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
- 125000005432 dialkylcarboxamide group Chemical group 0.000 claims description 2
- DRRWBCNQOKKKOL-UHFFFAOYSA-N eupatilin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(O)C(OC)=C(O)C=C2O1 DRRWBCNQOKKKOL-UHFFFAOYSA-N 0.000 claims description 2
- KDGKTJGPFXIBEB-UHFFFAOYSA-N n-hydroxyformamide Chemical class ONC=O KDGKTJGPFXIBEB-UHFFFAOYSA-N 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- MEJSICWGUXRRQX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-(2-hydroxyethoxy)-5-methoxychromen-4-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C=C(OCCO)C=C2O1 MEJSICWGUXRRQX-UHFFFAOYSA-N 0.000 claims 1
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000005392 carboxamide group Chemical class NC(=O)* 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 abstract description 18
- 231100000397 ulcer Toxicity 0.000 abstract description 15
- 230000001681 protective effect Effects 0.000 abstract description 14
- 208000007882 Gastritis Diseases 0.000 abstract description 10
- 238000005481 NMR spectroscopy Methods 0.000 description 105
- 238000002360 preparation method Methods 0.000 description 66
- 238000000034 method Methods 0.000 description 56
- 239000007858 starting material Substances 0.000 description 37
- 239000000243 solution Substances 0.000 description 30
- 230000002829 reductive effect Effects 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 20
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 18
- 239000000047 product Substances 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 230000003902 lesion Effects 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 238000006243 chemical reaction Methods 0.000 description 16
- 239000002904 solvent Substances 0.000 description 15
- 239000000203 mixture Substances 0.000 description 13
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 150000003180 prostaglandins Chemical class 0.000 description 12
- 210000001156 gastric mucosa Anatomy 0.000 description 11
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000700159 Rattus Species 0.000 description 9
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 8
- 238000004821 distillation Methods 0.000 description 8
- 239000003960 organic solvent Substances 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 208000007107 Stomach Ulcer Diseases 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 150000002207 flavanone derivatives Chemical class 0.000 description 7
- 210000000440 neutrophil Anatomy 0.000 description 7
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 7
- 239000003642 reactive oxygen metabolite Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 210000002784 stomach Anatomy 0.000 description 7
- DHPZTYWSWZIJME-UHFFFAOYSA-N 1-(6-hydroxy-2,3-dimethoxy-4-phenylmethoxyphenyl)ethanone Chemical compound C1=C(O)C(C(C)=O)=C(OC)C(OC)=C1OCC1=CC=CC=C1 DHPZTYWSWZIJME-UHFFFAOYSA-N 0.000 description 6
- NUJCNNARSCKFIJ-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-hydroxy-5-methoxychromen-4-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C=C(O)C=C2O1 NUJCNNARSCKFIJ-UHFFFAOYSA-N 0.000 description 6
- QMQAOYFHVBKQCG-UHFFFAOYSA-N 7-hydroxy-5,6-dimethoxy-2-phenylchromen-4-one Chemical compound C=1C(=O)C2=C(OC)C(OC)=C(O)C=C2OC=1C1=CC=CC=C1 QMQAOYFHVBKQCG-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 210000001072 colon Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 5
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 5
- 230000009858 acid secretion Effects 0.000 description 5
- 239000007810 chemical reaction solvent Substances 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 201000005917 gastric ulcer Diseases 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000002429 large intestine Anatomy 0.000 description 5
- 150000002617 leukotrienes Chemical class 0.000 description 5
- 210000003097 mucus Anatomy 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 4
- KFMFKHCKPGKKNV-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5,6-dimethoxychromen-4-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=CC=C2O1 KFMFKHCKPGKKNV-UHFFFAOYSA-N 0.000 description 4
- YSPUEGILIMCUPB-UHFFFAOYSA-N 6-Hydroxyluteolin 5,6-dimethyl ether Natural products C=1C(=O)C2=C(OC)C(OC)=C(O)C=C2OC=1C1=CC=C(O)C(O)=C1 YSPUEGILIMCUPB-UHFFFAOYSA-N 0.000 description 4
- QZNYGJAJWILZLF-UHFFFAOYSA-N 7-Hydroxy-3',4',5,6-tetramethoxyflavone Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(O)C=C2O1 QZNYGJAJWILZLF-UHFFFAOYSA-N 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 4
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 230000000767 anti-ulcer Effects 0.000 description 4
- 229940114079 arachidonic acid Drugs 0.000 description 4
- 235000021342 arachidonic acid Nutrition 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 239000012267 brine Substances 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 238000004440 column chromatography Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 229930003935 flavonoid Natural products 0.000 description 4
- 235000017173 flavonoids Nutrition 0.000 description 4
- 210000004969 inflammatory cell Anatomy 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 4
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 4
- UJHNTLLNAQELQO-UHFFFAOYSA-N pectolinaringenin Natural products C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(O)C=C2O1 UJHNTLLNAQELQO-UHFFFAOYSA-N 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 229950004535 rebamipide Drugs 0.000 description 4
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
- AGQNLHOTLJFJCG-UHFFFAOYSA-N 1-(2-hydroxy-4-phenylmethoxyphenyl)ethanone Chemical compound C1=C(O)C(C(=O)C)=CC=C1OCC1=CC=CC=C1 AGQNLHOTLJFJCG-UHFFFAOYSA-N 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 3
- GCRIYTXLBIHVLL-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-hydroxy-5-methoxy-6-pentoxychromen-4-one Chemical compound C=1C(=O)C2=C(OC)C(OCCCCC)=C(O)C=C2OC=1C1=CC=C(OC)C(OC)=C1 GCRIYTXLBIHVLL-UHFFFAOYSA-N 0.000 description 3
- FMJQLWHWTVZCDI-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-hydroxy-6-methoxychromen-4-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=CC(OC)=C(O)C=C2O1 FMJQLWHWTVZCDI-UHFFFAOYSA-N 0.000 description 3
- YCUAUHMEWQKIBU-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-hydroxy-6-pentoxychromen-4-one Chemical compound C1=C(O)C(OCCCCC)=CC(C(C=2)=O)=C1OC=2C1=CC=C(OC)C(OC)=C1 YCUAUHMEWQKIBU-UHFFFAOYSA-N 0.000 description 3
- IFHWIIUQNVRPOF-UHFFFAOYSA-N 5-methoxy-2-(4-methoxy-3-phenylmethoxyphenyl)-7-phenylmethoxychromen-4-one Chemical compound COC1=CC=C(C=2OC3=CC(OCC=4C=CC=CC=4)=CC(OC)=C3C(=O)C=2)C=C1OCC1=CC=CC=C1 IFHWIIUQNVRPOF-UHFFFAOYSA-N 0.000 description 3
- WYMUERAGNWQFGG-UHFFFAOYSA-N 6-butoxy-2-(3,4-dimethoxyphenyl)-7-hydroxy-5-methoxychromen-4-one Chemical compound C=1C(=O)C2=C(OC)C(OCCCC)=C(O)C=C2OC=1C1=CC=C(OC)C(OC)=C1 WYMUERAGNWQFGG-UHFFFAOYSA-N 0.000 description 3
- ZZJVFKUQMMYLNU-UHFFFAOYSA-N 7-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-5,6-dimethoxychromen-4-one Chemical compound C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(O)C=C2O1 ZZJVFKUQMMYLNU-UHFFFAOYSA-N 0.000 description 3
- FBIIRJKPTNBRSW-UHFFFAOYSA-N 7-hydroxy-6-pentoxy-2-phenylchromen-4-one Chemical compound C1=C(O)C(OCCCCC)=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 FBIIRJKPTNBRSW-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 102000001381 Arachidonate 5-Lipoxygenase Human genes 0.000 description 3
- 108010093579 Arachidonate 5-lipoxygenase Proteins 0.000 description 3
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 3
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
- QAGGICSUEVNSGH-UHFFFAOYSA-N Diosmetin Natural products C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=CC=C(O)C=C2O1 QAGGICSUEVNSGH-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- MBNGWHIJMBWFHU-UHFFFAOYSA-N diosmetin Chemical compound C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 MBNGWHIJMBWFHU-UHFFFAOYSA-N 0.000 description 3
- 208000000718 duodenal ulcer Diseases 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 description 3
- 229960004963 mesalazine Drugs 0.000 description 3
- 230000037353 metabolic pathway Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- FAQYAMRNWDIXMY-UHFFFAOYSA-N trichloroborane Chemical compound ClB(Cl)Cl FAQYAMRNWDIXMY-UHFFFAOYSA-N 0.000 description 3
- AOLOMULCAJQEIG-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5,7-dihydroxychromen-4-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 AOLOMULCAJQEIG-UHFFFAOYSA-N 0.000 description 2
- LHIMKWBTJLXXKZ-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-6-ethoxy-7-hydroxy-5-methoxychromen-4-one Chemical compound C=1C(=O)C2=C(OC)C(OCC)=C(O)C=C2OC=1C1=CC=C(OC)C(OC)=C1 LHIMKWBTJLXXKZ-UHFFFAOYSA-N 0.000 description 2
- BLUZKSFUMREPGB-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-hydroxy-5-methoxy-2,3-dihydrochromen-4-one Chemical compound C1=C(OC)C(OC)=CC=C1C1OC2=CC(O)=CC(OC)=C2C(=O)C1 BLUZKSFUMREPGB-UHFFFAOYSA-N 0.000 description 2
- CIEBZGAANAHGPY-UHFFFAOYSA-N 2-[2-(3,4-dimethoxyphenyl)-4-oxo-5-phenylmethoxychromen-7-yl]oxyacetic acid Chemical compound C1=C(OC)C(OC)=CC=C1C(OC1=CC(OCC(O)=O)=C2)=CC(=O)C1=C2OCC1=CC=CC=C1 CIEBZGAANAHGPY-UHFFFAOYSA-N 0.000 description 2
- UPWMKFWVYPJHCW-UHFFFAOYSA-N 2-[2-(3,4-dimethoxyphenyl)-5,6-dimethoxy-4-oxochromen-7-yl]oxyacetic acid Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OCC(O)=O)C=C2O1 UPWMKFWVYPJHCW-UHFFFAOYSA-N 0.000 description 2
- BCPQOBQIVJZOFL-UHFFFAOYSA-N 2-[2-(3,4-dimethoxyphenyl)-5-methoxy-4-oxochromen-7-yl]oxyacetic acid Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C=C(OCC(O)=O)C=C2O1 BCPQOBQIVJZOFL-UHFFFAOYSA-N 0.000 description 2
- FPRVEQAYURPPAI-UHFFFAOYSA-N 2-hydroxy-1-(3-methoxyphenyl)ethanone Chemical compound COC1=CC=CC(C(=O)CO)=C1 FPRVEQAYURPPAI-UHFFFAOYSA-N 0.000 description 2
- JMTMSDXUXJISAY-UHFFFAOYSA-N 2H-benzotriazol-4-ol Chemical compound OC1=CC=CC2=C1N=NN2 JMTMSDXUXJISAY-UHFFFAOYSA-N 0.000 description 2
- AWXFHJXPYIPUSS-UHFFFAOYSA-N 3,5,6-trimethoxy-2-phenylchromen-4-one Chemical compound COC=1C(=O)C2=C(OC)C(OC)=CC=C2OC=1C1=CC=CC=C1 AWXFHJXPYIPUSS-UHFFFAOYSA-N 0.000 description 2
- UXUQVAJOPMDUOA-UHFFFAOYSA-N 3-(2-hydroxy-5-pentoxy-4-phenylmethoxyphenyl)-1-phenylprop-2-en-1-one Chemical compound OC=1C=C(OCC=2C=CC=CC=2)C(OCCCCC)=CC=1C=CC(=O)C1=CC=CC=C1 UXUQVAJOPMDUOA-UHFFFAOYSA-N 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- VCWFILUULGOFCD-UHFFFAOYSA-N Desmethoxycentaureidin Natural products C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=C(O)C(OC)=C(O)C=C2O1 VCWFILUULGOFCD-UHFFFAOYSA-N 0.000 description 2
- 101000818522 Homo sapiens fMet-Leu-Phe receptor Proteins 0.000 description 2
- 206010020565 Hyperaemia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000006482 condensation reaction Methods 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- DZGCGKFAPXFTNM-UHFFFAOYSA-N ethanol;hydron;chloride Chemical compound Cl.CCO DZGCGKFAPXFTNM-UHFFFAOYSA-N 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical class CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- 210000000416 exudates and transudate Anatomy 0.000 description 2
- 102100021145 fMet-Leu-Phe receptor Human genes 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 150000002215 flavonoids Chemical class 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 208000009326 ileitis Diseases 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 2
- 230000023404 leukocyte cell-cell adhesion Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000012457 nonaqueous media Substances 0.000 description 2
- LKOJGSWUMISDOF-UHFFFAOYSA-N oroxylin A Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=CC=C1 LKOJGSWUMISDOF-UHFFFAOYSA-N 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- 210000003200 peritoneal cavity Anatomy 0.000 description 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- LKMNXYDUQXAUCZ-UHFFFAOYSA-N sinensetin Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C=C2O1 LKMNXYDUQXAUCZ-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000036269 ulceration Effects 0.000 description 2
- WJUFSDZVCOTFON-UHFFFAOYSA-N veratraldehyde Chemical compound COC1=CC=C(C=O)C=C1OC WJUFSDZVCOTFON-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 1
- WNMUZQQSHFGUPS-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-3-(2-hydroxy-5-methoxy-4-phenylmethoxyphenyl)prop-2-en-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)C=CC(C(=C1)O)=CC(OC)=C1OCC1=CC=CC=C1 WNMUZQQSHFGUPS-UHFFFAOYSA-N 0.000 description 1
- KPTQMFRDVNISCC-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-3-(2-hydroxy-5-pentoxy-4-phenylmethoxyphenyl)prop-2-en-1-one Chemical compound OC=1C=C(OCC=2C=CC=CC=2)C(OCCCCC)=CC=1C=CC(=O)C1=CC=C(OC)C(OC)=C1 KPTQMFRDVNISCC-UHFFFAOYSA-N 0.000 description 1
- DBYUIWISBIXCLL-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-3-(2-hydroxy-6-methoxy-4-phenylmethoxyphenyl)prop-2-en-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)C=CC(C(=C1)OC)=C(O)C=C1OCC1=CC=CC=C1 DBYUIWISBIXCLL-UHFFFAOYSA-N 0.000 description 1
- OUBLWJBLKGJHGH-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-3-(2-hydroxy-6-methoxyphenyl)prop-2-en-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)C=CC1=C(O)C=CC=C1OC OUBLWJBLKGJHGH-UHFFFAOYSA-N 0.000 description 1
- HWCKQUQXTNNKPC-UHFFFAOYSA-N 1-(3,4-dimethoxyphenyl)-3-(6-hydroxy-2,3-dimethoxy-4-phenylmethoxyphenyl)prop-2-en-1-one Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)C=CC(C(=C1OC)OC)=C(O)C=C1OCC1=CC=CC=C1 HWCKQUQXTNNKPC-UHFFFAOYSA-N 0.000 description 1
- DZWSONAXHVOIRB-UHFFFAOYSA-N 1-[3,4-bis(phenylmethoxy)phenyl]-3-(6-hydroxy-2,3-dimethoxy-4-phenylmethoxyphenyl)prop-2-en-1-one Chemical compound C1=C(O)C(C=CC(=O)C=2C=C(OCC=3C=CC=CC=3)C(OCC=3C=CC=CC=3)=CC=2)=C(OC)C(OC)=C1OCC1=CC=CC=C1 DZWSONAXHVOIRB-UHFFFAOYSA-N 0.000 description 1
- ZWJIJEOIENYKPK-UHFFFAOYSA-N 1-phenyl-3-(2-propoxyphenyl)prop-2-en-1-one Chemical compound CCCOC1=CC=CC=C1C=CC(=O)C1=CC=CC=C1 ZWJIJEOIENYKPK-UHFFFAOYSA-N 0.000 description 1
- LNBMZFHIYRDKNS-UHFFFAOYSA-N 2,2-dimethoxy-1-phenylethanone Chemical compound COC(OC)C(=O)C1=CC=CC=C1 LNBMZFHIYRDKNS-UHFFFAOYSA-N 0.000 description 1
- JEXGFZJQCDNOKP-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5,7-dihydroxy-6-methoxy-2,3-dihydrochromen-4-one Chemical compound C1=C(OC)C(OC)=CC=C1C1OC2=CC(O)=C(OC)C(O)=C2C(=O)C1 JEXGFZJQCDNOKP-UHFFFAOYSA-N 0.000 description 1
- PBYZCZLMNNLEST-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5,7-dihydroxy-6-pentoxychromen-4-one Chemical compound C=1C(=O)C2=C(O)C(OCCCCC)=C(O)C=C2OC=1C1=CC=C(OC)C(OC)=C1 PBYZCZLMNNLEST-UHFFFAOYSA-N 0.000 description 1
- DUDWMXTZMWXQKG-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5,7-dihydroxy-6-propoxychromen-4-one Chemical compound C=1C(=O)C2=C(O)C(OCCC)=C(O)C=C2OC=1C1=CC=C(OC)C(OC)=C1 DUDWMXTZMWXQKG-UHFFFAOYSA-N 0.000 description 1
- ARTQMAIQLBBPJR-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5,7-dihydroxychromen-4-one 2-(3,4-dimethoxyphenyl)-5-methoxy-7-phenylmethoxychromen-4-one Chemical compound C(C1=CC=CC=C1)OC1=CC(=C2C(C=C(OC2=C1)C1=CC(=C(C=C1)OC)OC)=O)OC.OC1=C2C(C=C(OC2=CC(=C1)O)C1=CC(=C(C=C1)OC)OC)=O ARTQMAIQLBBPJR-UHFFFAOYSA-N 0.000 description 1
- QEWSAPKRFOFQIU-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-6,7-dimethoxychromen-4-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(O)C(OC)=C(OC)C=C2O1 QEWSAPKRFOFQIU-UHFFFAOYSA-N 0.000 description 1
- UREKJGMIOXFLPE-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-methoxy-6-pentoxy-7-phenylmethoxychromen-4-one Chemical compound C1=C2OC(C=3C=C(OC)C(OC)=CC=3)=CC(=O)C2=C(OC)C(OCCCCC)=C1OCC1=CC=CC=C1 UREKJGMIOXFLPE-UHFFFAOYSA-N 0.000 description 1
- DLXWZZSLBNPGOY-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-methoxy-7-phenylmethoxychromen-4-one Chemical compound C1=C(OC)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(OC)C=C2OCC1=CC=CC=C1 DLXWZZSLBNPGOY-UHFFFAOYSA-N 0.000 description 1
- IIOQEHSFZUYICM-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-methoxychromen-4-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C=CC=C2O1 IIOQEHSFZUYICM-UHFFFAOYSA-N 0.000 description 1
- IHOUPGIKPDNXRG-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-6-ethoxy-5,7-dihydroxychromen-4-one Chemical compound C=1C(=O)C2=C(O)C(OCC)=C(O)C=C2OC=1C1=CC=C(OC)C(OC)=C1 IHOUPGIKPDNXRG-UHFFFAOYSA-N 0.000 description 1
- BMQOJEGOLDRJPL-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-6-ethoxy-5-methoxy-7-phenylmethoxychromen-4-one Chemical compound C1=C2OC(C=3C=C(OC)C(OC)=CC=3)=CC(=O)C2=C(OC)C(OCC)=C1OCC1=CC=CC=C1 BMQOJEGOLDRJPL-UHFFFAOYSA-N 0.000 description 1
- LAMCJLIVPRMIEB-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-6-methoxy-7-phenylmethoxychromen-4-one Chemical compound C1=C(OC)C(OC)=CC=C1C(OC1=C2)=CC(=O)C1=CC(OC)=C2OCC1=CC=CC=C1 LAMCJLIVPRMIEB-UHFFFAOYSA-N 0.000 description 1
- QYDMYMLHNGOWLE-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-6-methoxychromen-4-one Chemical compound C=1C(=O)C2=CC(OC)=CC=C2OC=1C1=CC=C(OC)C(OC)=C1 QYDMYMLHNGOWLE-UHFFFAOYSA-N 0.000 description 1
- GGXADKJRYPGAGL-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-6-pentoxy-7-phenylmethoxychromen-4-one Chemical compound CCCCCOC1=CC(C(C=C(O2)C=3C=C(OC)C(OC)=CC=3)=O)=C2C=C1OCC1=CC=CC=C1 GGXADKJRYPGAGL-UHFFFAOYSA-N 0.000 description 1
- GHIDENQNBRLAMY-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-(2-hydroxyethoxy)-5,6-dimethoxychromen-4-one Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OCCO)C=C2O1 GHIDENQNBRLAMY-UHFFFAOYSA-N 0.000 description 1
- AEBVMCKIXJLXBN-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-(2-hydroxyethoxy)-5-methoxychromen-4-one 2-(3,4-dimethoxyphenyl)-7-hydroxy-5-methoxychromen-4-one Chemical compound OC1=CC(=C2C(C=C(OC2=C1)C1=CC(=C(C=C1)OC)OC)=O)OC.OCCOC1=CC(=C2C(C=C(OC2=C1)C1=CC(=C(C=C1)OC)OC)=O)OC AEBVMCKIXJLXBN-UHFFFAOYSA-N 0.000 description 1
- UOZLUYOYRJLSQN-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-7-hydroxy-5-methoxy-6-propoxychromen-4-one Chemical compound C=1C(=O)C2=C(OC)C(OCCC)=C(O)C=C2OC=1C1=CC=C(OC)C(OC)=C1 UOZLUYOYRJLSQN-UHFFFAOYSA-N 0.000 description 1
- KMZLUSUMKZLCBD-UHFFFAOYSA-N 2-(4-fluorophenyl)-5-methoxychromen-4-one Chemical compound C=1C(=O)C=2C(OC)=CC=CC=2OC=1C1=CC=C(F)C=C1 KMZLUSUMKZLCBD-UHFFFAOYSA-N 0.000 description 1
- HAPBULAFJYNCCL-UHFFFAOYSA-N 2-(4-oxo-6-pentoxy-2-phenylchromen-7-yl)oxyacetic acid Chemical compound C1=C(OCC(O)=O)C(OCCCCC)=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 HAPBULAFJYNCCL-UHFFFAOYSA-N 0.000 description 1
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
- FCSBOBHPBJJGBJ-UHFFFAOYSA-N 2-[2-(3,4-dimethoxyphenyl)-4-oxo-6-pentoxychromen-7-yl]oxyacetic acid Chemical compound C1=C(OCC(O)=O)C(OCCCCC)=CC(C(C=2)=O)=C1OC=2C1=CC=C(OC)C(OC)=C1 FCSBOBHPBJJGBJ-UHFFFAOYSA-N 0.000 description 1
- GUKSXARYYJIQAL-UHFFFAOYSA-N 2-[2-(3,4-dimethoxyphenyl)-5-hydroxy-4-oxo-6-propoxychromen-7-yl]oxyacetic acid Chemical compound C=1C(=O)C2=C(O)C(OCCC)=C(OCC(O)=O)C=C2OC=1C1=CC=C(OC)C(OC)=C1 GUKSXARYYJIQAL-UHFFFAOYSA-N 0.000 description 1
- ZVZSPSHBDZXKFO-UHFFFAOYSA-N 2-[2-(3,4-dimethoxyphenyl)-5-hydroxy-4-oxochromen-7-yl]oxyacetic acid Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(OCC(O)=O)C=C2O1 ZVZSPSHBDZXKFO-UHFFFAOYSA-N 0.000 description 1
- AGBODBJRABIDBB-UHFFFAOYSA-N 2-[2-(3,4-dimethoxyphenyl)-5-hydroxy-6-methoxy-4-oxochromen-7-yl]oxyacetic acid Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=C(O)C(OC)=C(OCC(O)=O)C=C2O1 AGBODBJRABIDBB-UHFFFAOYSA-N 0.000 description 1
- NNAGEHZFPCWTQM-UHFFFAOYSA-N 2-[2-(3,4-dimethoxyphenyl)-6-methoxy-4-oxochromen-7-yl]oxyacetic acid Chemical compound C1=C(OC)C(OC)=CC=C1C1=CC(=O)C2=CC(OC)=C(OCC(O)=O)C=C2O1 NNAGEHZFPCWTQM-UHFFFAOYSA-N 0.000 description 1
- XKYSZYSMXNUAOC-UHFFFAOYSA-N 2-[3,4-bis(phenylmethoxy)phenyl]-5,6-dimethoxy-7-phenylmethoxychromen-4-one Chemical compound C1=C2OC(C=3C=C(OCC=4C=CC=CC=4)C(OCC=4C=CC=CC=4)=CC=3)=CC(=O)C2=C(OC)C(OC)=C1OCC1=CC=CC=C1 XKYSZYSMXNUAOC-UHFFFAOYSA-N 0.000 description 1
- ADNALZBNHVQRQA-UHFFFAOYSA-N 2-[5-butoxy-2-(3,4-dimethoxyphenyl)-4-oxochromen-7-yl]oxyacetic acid Chemical compound C=1C(=O)C=2C(OCCCC)=CC(OCC(O)=O)=CC=2OC=1C1=CC=C(OC)C(OC)=C1 ADNALZBNHVQRQA-UHFFFAOYSA-N 0.000 description 1
- HUOFTGPLBDNSIZ-UHFFFAOYSA-N 2-[5-cyclopentyloxy-2-(3,4-dimethoxyphenyl)-4-oxochromen-7-yl]oxyacetic acid Chemical compound C1=C(OC)C(OC)=CC=C1C(OC1=CC(OCC(O)=O)=C2)=CC(=O)C1=C2OC1CCCC1 HUOFTGPLBDNSIZ-UHFFFAOYSA-N 0.000 description 1
- DMLHZQCXAJAXOY-UHFFFAOYSA-N 2-[5-hydroxy-6-methoxy-2-(4-methoxyphenyl)-4-oxochromen-7-yl]oxyacetic acid Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C(OC)=C(OCC(O)=O)C=C2O1 DMLHZQCXAJAXOY-UHFFFAOYSA-N 0.000 description 1
- XIEYTSSHRZRSKW-UHFFFAOYSA-N 2-[6-butoxy-2-(3,4-dimethoxyphenyl)-5-hydroxy-4-oxochromen-7-yl]oxyacetic acid Chemical compound C=1C(=O)C2=C(O)C(OCCCC)=C(OCC(O)=O)C=C2OC=1C1=CC=C(OC)C(OC)=C1 XIEYTSSHRZRSKW-UHFFFAOYSA-N 0.000 description 1
- ZNBDVTRCNUYWPN-UHFFFAOYSA-N 2-[[2-(3,4-dimethoxyphenyl)-5-hydroxy-6-methoxy-4-oxo-2,3-dihydrochromen-7-yl]oxy]acetic acid Chemical compound C1=C(OC)C(OC)=CC=C1C1OC2=CC(OCC(O)=O)=C(OC)C(O)=C2C(=O)C1 ZNBDVTRCNUYWPN-UHFFFAOYSA-N 0.000 description 1
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 1
- UFGARDSCOTVPTF-UHFFFAOYSA-N 3-(2-hydroxy-6-methoxy-4-phenylmethoxyphenyl)-1-(4-methoxy-3-phenylmethoxyphenyl)prop-2-en-1-one Chemical compound COC1=CC=C(C(=O)C=CC=2C(=CC(OCC=3C=CC=CC=3)=CC=2O)OC)C=C1OCC1=CC=CC=C1 UFGARDSCOTVPTF-UHFFFAOYSA-N 0.000 description 1
- ZULQQHKSHFGXKM-UHFFFAOYSA-N 3-(3-butoxy-6-hydroxy-2-methoxy-4-phenylmethoxyphenyl)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one Chemical compound C1=C(O)C(C=CC(=O)C=2C=C(OC)C(OC)=CC=2)=C(OC)C(OCCCC)=C1OCC1=CC=CC=C1 ZULQQHKSHFGXKM-UHFFFAOYSA-N 0.000 description 1
- CWJZKOYOFJKAKH-UHFFFAOYSA-N 3-(6-hydroxy-2,3-dimethoxy-4-phenylmethoxyphenyl)-1-(4-methoxy-3-phenylmethoxyphenyl)prop-2-en-1-one Chemical compound COC1=CC=C(C(=O)C=CC=2C(=C(OC)C(OCC=3C=CC=CC=3)=CC=2O)OC)C=C1OCC1=CC=CC=C1 CWJZKOYOFJKAKH-UHFFFAOYSA-N 0.000 description 1
- KHYSFUQUTHWDAI-UHFFFAOYSA-N 3-(6-hydroxy-2,3-dimethoxy-4-phenylmethoxyphenyl)-1-(4-methoxyphenyl)prop-2-en-1-one Chemical compound C1=CC(OC)=CC=C1C(=O)C=CC(C(=C1OC)OC)=C(O)C=C1OCC1=CC=CC=C1 KHYSFUQUTHWDAI-UHFFFAOYSA-N 0.000 description 1
- IQZCCZSNTWGRPG-UHFFFAOYSA-N 3-(6-hydroxy-2,3-dimethoxy-4-phenylmethoxyphenyl)-1-phenylprop-2-en-1-one Chemical compound C1=C(O)C(C=CC(=O)C=2C=CC=CC=2)=C(OC)C(OC)=C1OCC1=CC=CC=C1 IQZCCZSNTWGRPG-UHFFFAOYSA-N 0.000 description 1
- ZAIANDVQAMEDFL-UHFFFAOYSA-N 3-methoxy-2-phenylchromen-4-one Chemical compound O1C2=CC=CC=C2C(=O)C(OC)=C1C1=CC=CC=C1 ZAIANDVQAMEDFL-UHFFFAOYSA-N 0.000 description 1
- JJPXUDKPWPXSHS-UHFFFAOYSA-N 5,6-dimethoxy-2-(4-methoxy-3-phenylmethoxyphenyl)-7-phenylmethoxychromen-4-one Chemical compound COC1=CC=C(C=2OC3=CC(OCC=4C=CC=CC=4)=C(OC)C(OC)=C3C(=O)C=2)C=C1OCC1=CC=CC=C1 JJPXUDKPWPXSHS-UHFFFAOYSA-N 0.000 description 1
- PZHVTUHSIPYLMO-UHFFFAOYSA-N 5,6-dimethoxy-2-(4-methoxyphenyl)-7-phenylmethoxychromen-4-one Chemical compound C1=CC(OC)=CC=C1C(OC1=C2)=CC(=O)C1=C(OC)C(OC)=C2OCC1=CC=CC=C1 PZHVTUHSIPYLMO-UHFFFAOYSA-N 0.000 description 1
- HPLDKPBKVPIJRD-UHFFFAOYSA-N 5,6-dimethoxy-2-phenyl-7-phenylmethoxychromen-4-one Chemical compound C1=C2OC(C=3C=CC=CC=3)=CC(=O)C2=C(OC)C(OC)=C1OCC1=CC=CC=C1 HPLDKPBKVPIJRD-UHFFFAOYSA-N 0.000 description 1
- DANYIYRPLHHOCZ-UHFFFAOYSA-N 5,7-dihydroxy-4'-methoxyflavone Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 DANYIYRPLHHOCZ-UHFFFAOYSA-N 0.000 description 1
- KFGOFTHODYBSGM-IJCBKZNRSA-N 6-Keto-prostaglandin F1a Chemical compound CCCCC[C@H](O)C=C[C@H]1[C@H](O)C[C@H](O)[C@@H]1CC(=O)CCCCC(O)=O KFGOFTHODYBSGM-IJCBKZNRSA-N 0.000 description 1
- KDRWVKQCOVKEDL-UHFFFAOYSA-N 6-butoxy-2-(3,4-dimethoxyphenyl)-5,7-dihydroxychromen-4-one Chemical compound C=1C(=O)C2=C(O)C(OCCCC)=C(O)C=C2OC=1C1=CC=C(OC)C(OC)=C1 KDRWVKQCOVKEDL-UHFFFAOYSA-N 0.000 description 1
- HGHGCKJAWJPMHA-UHFFFAOYSA-N 6-butoxy-2-(3,4-dimethoxyphenyl)-5-methoxy-7-phenylmethoxychromen-4-one Chemical compound C1=C2OC(C=3C=C(OC)C(OC)=CC=3)=CC(=O)C2=C(OC)C(OCCCC)=C1OCC1=CC=CC=C1 HGHGCKJAWJPMHA-UHFFFAOYSA-N 0.000 description 1
- PLMQPUMQUSZTKI-UHFFFAOYSA-N 6-pentoxy-2-phenyl-7-phenylmethoxychromen-4-one Chemical compound CCCCCOC1=CC(C(C=C(O2)C=3C=CC=CC=3)=O)=C2C=C1OCC1=CC=CC=C1 PLMQPUMQUSZTKI-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- MMJJKUZTMBECSF-UHFFFAOYSA-N C1=C(OC)C(OC)=CC=C1C1OC(C=C(OCC=2C=CC=CC=2)C(OC)=C2OC)=C2C(=O)C1 Chemical compound C1=C(OC)C(OC)=CC=C1C1OC(C=C(OCC=2C=CC=CC=2)C(OC)=C2OC)=C2C(=O)C1 MMJJKUZTMBECSF-UHFFFAOYSA-N 0.000 description 1
- DANUDMGTMGHVSU-UHFFFAOYSA-N CCCCCOC1=CC=2C(=O)CC(C=3C=CC=CC=3)OC=2C=C1OCC1=CC=CC=C1 Chemical compound CCCCCOC1=CC=2C(=O)CC(C=3C=CC=CC=3)OC=2C=C1OCC1=CC=CC=C1 DANUDMGTMGHVSU-UHFFFAOYSA-N 0.000 description 1
- DRSHXJFUUPIBHX-UHFFFAOYSA-N COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 Chemical compound COc1ccc(cc1)N1N=CC2C=NC(Nc3cc(OC)c(OC)c(OCCCN4CCN(C)CC4)c3)=NC12 DRSHXJFUUPIBHX-UHFFFAOYSA-N 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- MTVPOQKYYUETRT-UHFFFAOYSA-N Eupatilin Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 MTVPOQKYYUETRT-UHFFFAOYSA-N 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 206010061164 Gastric mucosal lesion Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 description 1
- 229940119157 Hydroxy radical scavenger Drugs 0.000 description 1
- 238000004566 IR spectroscopy Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- GOMNNFRNMNSQSI-UHFFFAOYSA-N O1C=2C=C(O)C(OCCCCC)=CC=2C(=O)CC1C1=CC=CC=C1 Chemical compound O1C=2C=C(O)C(OCCCCC)=CC=2C(=O)CC1C1=CC=CC=C1 GOMNNFRNMNSQSI-UHFFFAOYSA-N 0.000 description 1
- AKUZESDPUWXDNY-UHFFFAOYSA-N O1C=2C=C(OCC(O)=O)C(OCCCCC)=CC=2C(=O)CC1C1=CC=CC=C1 Chemical compound O1C=2C=C(OCC(O)=O)C(OCCCCC)=CC=2C(=O)CC1C1=CC=CC=C1 AKUZESDPUWXDNY-UHFFFAOYSA-N 0.000 description 1
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- BJBKXYIIWYIZCX-UHFFFAOYSA-N Trigraecum Natural products C1=C(O)C(OC)=CC(C(C=2)=O)=C1OC=2C1=CC=CC=C1 BJBKXYIIWYIZCX-UHFFFAOYSA-N 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000009056 active transport Effects 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 230000002590 anti-leukotriene effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 210000003989 endothelium vascular Anatomy 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 150000002208 flavanones Chemical class 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 description 1
- 229940025878 hesperidin Drugs 0.000 description 1
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- FUKUFMFMCZIRNT-UHFFFAOYSA-N hydron;methanol;chloride Chemical compound Cl.OC FUKUFMFMCZIRNT-UHFFFAOYSA-N 0.000 description 1
- RGZRSLKIOCHTSI-UHFFFAOYSA-N hydron;n-methylhydroxylamine;chloride Chemical compound Cl.CNO RGZRSLKIOCHTSI-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 239000002555 ionophore Substances 0.000 description 1
- 230000000236 ionophoric effect Effects 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- YEHDMSUNJUONMW-UHFFFAOYSA-N methoxyflavone Natural products COC1=CC=CC=C1C1=CC(=O)C2=CC=CC=C2O1 YEHDMSUNJUONMW-UHFFFAOYSA-N 0.000 description 1
- YDCHPLOFQATIDS-UHFFFAOYSA-N methyl 2-bromoacetate Chemical compound COC(=O)CBr YDCHPLOFQATIDS-UHFFFAOYSA-N 0.000 description 1
- OJLOPKGSLYJEMD-URPKTTJQSA-N methyl 7-[(1r,2r,3r)-3-hydroxy-2-[(1e)-4-hydroxy-4-methyloct-1-en-1-yl]-5-oxocyclopentyl]heptanoate Chemical compound CCCCC(C)(O)C\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-URPKTTJQSA-N 0.000 description 1
- 238000007431 microscopic evaluation Methods 0.000 description 1
- 229960005249 misoprostol Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- GPQLHGCIAUEJQK-UHFFFAOYSA-N pectolinarigenin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(O)C(OC)=C(O)C=C2O1 GPQLHGCIAUEJQK-UHFFFAOYSA-N 0.000 description 1
- KYDJXCOQYUPOKW-UHFFFAOYSA-N pectolinarigenin Natural products COc1c(O)cc2OC(=CC(=O)c2c1O)c3ccc(C)cc3 KYDJXCOQYUPOKW-UHFFFAOYSA-N 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 210000001187 pylorus Anatomy 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 208000037922 refractory disease Diseases 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 1
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 description 1
- 229960004291 sucralfate Drugs 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- 150000005622 tetraalkylammonium hydroxides Chemical class 0.000 description 1
- 229940073455 tetraethylammonium hydroxide Drugs 0.000 description 1
- LRGJRHZIDJQFCL-UHFFFAOYSA-M tetraethylazanium;hydroxide Chemical compound [OH-].CC[N+](CC)(CC)CC LRGJRHZIDJQFCL-UHFFFAOYSA-M 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.次の構造式(I)のフラボンまたはフラバノン化合物そしてこれらの薬学的 に許容可能な塩。 構造式I 前記構造式(I)でA、B、Cはそれぞれ同一または異なり、水素、ヒドロキ シ、置換されないまたは一つ置換されたアルキルオキシ、シクロアルキルオキシ である。 D、Eはそれぞれ同一または異なり、水素、ヒドロキシ、1個〜6個の炭素から なる直鎖または側鎖を有する低級アルキルオキシである。 2−と3−位間の結合は単一または二重結合である。 2.アルキルオキシの置換基がヒドロキシ、カルボキシ、カルボキシのアルキル エステル、カルボキサミド、N−モノまたはジアルキルカルボキサミド、N−ヒド ロキシカルボキサミド、N−ヒドロキシ−N−アルキルカルボキサミド、置換また は置換されていないベンゼン環でなるグループから選択されることを特徴とする 請求の範囲第1項記載の構造式(I)のフラボンまたはフラバノン化合物そして これら薬学的に許容可能な塩。 3.Aがヒドロキシ、Bがアルキルオキシ、C、D、Eがそれぞれ水素、ヒドロ キシ、アルキルオキシからなるグループから選択されることを特徴とする請求の 範囲第1項記載の構造式(I)のフラボンまたはフラバノン化合物そしてこれら 薬学的に許容可能な塩。 4.Aがヒドロキシ、Bは水素、C、D、Eがそれぞれ水素、ヒドロキシ、アル キルオキシからなるグループから選択されることを特徴とする請求の範囲第1項 記載のフラボンまたはフラバノン化合物そしてこれら薬学的に許容可能な塩。 5.A、Bが水素、C、D、Eがそれぞれ水素、ヒドロキシ、アルキルオキシか らなるグループから選択されることを特徴とする請求の範囲第1項記載のフラボ ンまたはフラバノン化合物そしてこれらの薬学的に許容可能な塩。 6.Aが水素、Bがアルキルオキシ、C、D、Eがそれぞれ水素、ヒドロキシ、 アルキルオキシからなるグループから選択されることを特徴とする請求の範囲第 1項記載のフラボンまたはフラバノン化合物そしてこれらの薬学的に許容可能な 塩。 7.Aがアルキルオキシカルボアルキルオキシ、B、C、D、Eがそれぞれ水素 、またはアルキルオキシであることを特徴とする請求の範囲第1項記載のフラボ ンまたはフラバノン化合物そしてこれらの薬学的に許容可能な塩。 8.Aがカルボキシアルキルオキシ、B、C、D、Eがそれぞれ水素、ヒドロキ シまたはアルキルオキシであることを特徴とする請求の範囲第1項記載のフラボ ンまたはフラバノン化合物そしてこれらの薬学的に許容可能な塩。 9.AがN−アルキルアミドアルキルオキシ、B、C、D、Eがそれぞれ水素ま たはアルキルオキシであることを特徴とする請求の範囲第1項記載のフラボンま たはフラバノン化合物そしてこれらの薬学的に許容可能な塩。 10.Aがヒドロキシアルキルオキシ、B、C、D、Eがそれぞれ水素またはア ルキルオキシであることを特徴とする請求の範囲第1項記載のフラボンまたはフ ラバノン化合物そしてこれらの薬学的に許容可能な塩。 11.構造式(I)の化合物が 3′,4′,6−トリメトキシ−5,7ジヒドロキシフラボン、 7−カルボキシメチルオキシ−3′,4′,5,6−テトラメトキシフラボン 7−カルボキシメチルオキシ−5−ヒドロキシ−3′,4′,6−トリメトキ シフラボン 7−カルボキシメチルオキシ−5−ヒドロキシ−3′,4′,6−トリメトキ シフラバノン 7−カルボキシメチルオキシ−3′,4′,5−トリメトキシフラボン 7−カルボキシメチルオキシ−3′,4′−ジメトキシフラボン−6−n−ペ ンチルオキシフラボン 7−カルボキシメチルオキシ−5−ヒドロキシ−6−n−ブチルオキシ−3′ ,4′−ジメトキシフラボン 7−N−メチルアミドメチルオキシ−3′,4′、5−トリメトキシフラボン 7−(N−ヒドロキシ−N−メチルアミドメチルオキシ−3′,4′,5−ト リメトキシフラボン、 7−ヒドロキシエチルオキシ−3′,4′,5−トリメトキシフラボン及び 7−ヒドロキシエチルオキシ−3′,4′,5,6−テトラメトキシフラボン からなるグループから選択されることを特徴とする請求の範囲第1項記載のフラ ボンまたはフラバノン化合物そしてこれら薬学的に許容可能な塩。 12.構造式(I)のブラボンまたはフラバノン化合物そしてこれら薬学的に許 容可能な塩を有効成分とする胃腸管粘膜損傷に対する予防及び治療や炎症性腸疾 病に対する治療剤用薬学的組成物。 13.A、B、Cが適切に置換された2−ヒドロキシアセトフェノンとD、Eが 適切に置換されたベンズアルデヒドをアルドール反応させ、カルコンを得、これ を環化して構造式(I)のフラボンまたはフラバノン化合物の骨格構造を作り、 2−ヒドロキシアセトフェノンとベンズアルデヒドにより適切に置換された保護 基を脱保護化し、目的の置換基を導入することを特徴とする構造式(I)の フラボンまたはフラバノン化合物の製造方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1019960030494A KR100447918B1 (ko) | 1996-07-25 | 1996-07-25 | 대장을포함한위장관보호작용을갖는플라본및플라바논화합물 |
KR1996/30494 | 1996-07-25 | ||
PCT/KR1997/000144 WO1998004541A1 (en) | 1996-07-25 | 1997-07-25 | Gastroprotective flavone/flavanone compounds with therapeutic effect on inflammatory bowel disease |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11514015A true JPH11514015A (ja) | 1999-11-30 |
JP3377214B2 JP3377214B2 (ja) | 2003-02-17 |
Family
ID=19467593
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50871298A Expired - Fee Related JP3377214B2 (ja) | 1996-07-25 | 1997-07-25 | 胃腸管保護作用により炎症性腸疾病で治癒効果を有するフラボン及びフラバノン化合物 |
Country Status (8)
Country | Link |
---|---|
US (1) | US6025387A (ja) |
EP (1) | EP0915864B1 (ja) |
JP (1) | JP3377214B2 (ja) |
KR (1) | KR100447918B1 (ja) |
CA (1) | CA2261267C (ja) |
DE (1) | DE69715216T2 (ja) |
DK (1) | DK0915864T3 (ja) |
WO (1) | WO1998004541A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001181190A (ja) * | 1999-12-22 | 2001-07-03 | Takeda Chem Ind Ltd | 医薬組成物 |
WO2006011669A1 (ja) * | 2004-07-28 | 2006-02-02 | Santen Pharmaceutical Co., Ltd. | 新規桂皮酸関連化合物 |
JP2006509720A (ja) * | 2002-05-17 | 2006-03-23 | メルクル・ゲーエムベーハー | 潰瘍治療用プロトンポンプ阻害剤としての環付加ピロール化合物 |
JP2007504217A (ja) * | 2003-09-04 | 2007-03-01 | ドン・ア・ファーム・カンパニー・リミテッド | 7−カルボキシメチルオキシ−3’,4’,5−トリメトキシフラボン一水和物、その製造方法及び用途 |
JP2009527461A (ja) * | 2006-01-09 | 2009-07-30 | カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ | 胃腸毒性、関連する症状及び潰瘍の処置のための天然作用物質 |
JP2010529112A (ja) * | 2007-06-07 | 2010-08-26 | ドン・ア・ファーム・カンパニー・リミテッド | 粘液分泌の刺激剤としての3’,4’,5−トリメトキシフラボン誘導体、その方法、および上記化合物を含んでなる医薬組成物 |
JP2012116785A (ja) * | 2010-11-30 | 2012-06-21 | Tsumura & Co | 5,7‐ジヒドロキシ‐6‐メトキシフラボン類の製造方法 |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19902773A1 (de) * | 1999-01-25 | 2000-07-27 | Sertuerner Arzneimittel Gmbh | Anticholestatische Wirksamkeit von Luteolin |
US7638554B2 (en) * | 2002-04-18 | 2009-12-29 | Sri International | Flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents |
US20030229136A1 (en) * | 2002-04-18 | 2003-12-11 | Nurulain Zaveri | Novel flavanoids as chemotherapeutic, chemopreventive, and antiangiogenic agents |
JP2006516562A (ja) * | 2003-01-24 | 2006-07-06 | ステート オブ イスラエル、ミニストリー オブ アグリカルチャー | 抗酸化活性を増強するための相乗的な組成物及び方法 |
US20040176471A1 (en) * | 2003-03-07 | 2004-09-09 | Kaohsiung Medical University | Novel chalcone derivatives and pharmaceutical compositions comprising the same |
EP2277595A3 (en) | 2004-06-24 | 2011-09-28 | Novartis Vaccines and Diagnostics, Inc. | Compounds for immunopotentiation |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
PE20070978A1 (es) * | 2006-02-14 | 2007-11-15 | Novartis Ag | COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks) |
TW200808739A (en) | 2006-04-06 | 2008-02-16 | Novartis Vaccines & Diagnostic | Quinazolines for PDK1 inhibition |
US20080319051A1 (en) * | 2007-06-22 | 2008-12-25 | Bionovo, Inc. | Liquiritigenin and derivatives as selective estrogen receptor beta agonists |
US20090042818A1 (en) * | 2007-06-22 | 2009-02-12 | Bionovo, Inc. | Liquiritigenin and Derivatives as Selective Estrogen Receptor Beta Agonists |
KR101381999B1 (ko) * | 2007-07-06 | 2014-04-14 | 동아에스티 주식회사 | 위염 치료제의 효력을 극대화시키기 위한 가용화 위체류시스템 매트릭스 제제 |
KR101391494B1 (ko) | 2007-11-26 | 2014-05-07 | 동아에스티 주식회사 | 위염 치료제의 효력을 극대화시키기 위한 나노서스펜젼 |
CA2710122A1 (en) | 2007-12-20 | 2009-07-02 | Novartis Ag | Thiazole derivatives used as pi 3 kinase inhibitors |
WO2009110008A1 (en) * | 2008-03-05 | 2009-09-11 | Council Of Scientific & Industrial Research | Anti-ulcer activity of flavone analogs |
EP2112145A1 (en) * | 2008-04-24 | 2009-10-28 | AxoGlia Therapeutics S.A. | Chromenone derivatives useful for the treatment of neurodegenerative diseases |
US8293753B2 (en) | 2009-07-02 | 2012-10-23 | Novartis Ag | Substituted 2-carboxamide cycloamino ureas |
AR082418A1 (es) | 2010-08-02 | 2012-12-05 | Novartis Ag | Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico |
PL2670753T3 (pl) | 2011-01-31 | 2017-05-31 | Novartis Ag | Nowe pochodne heterocykliczne |
MX340452B (es) | 2011-10-28 | 2016-07-08 | Novartis Ag | Novedosos derivados de purina y su uso en el tratamiento de enfermedades. |
WO2013173283A1 (en) | 2012-05-16 | 2013-11-21 | Novartis Ag | Dosage regimen for a pi-3 kinase inhibitor |
CA2930359C (en) | 2013-12-06 | 2022-03-01 | Novartis Ag | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor |
US10376488B2 (en) * | 2014-09-05 | 2019-08-13 | ONENESS BIOTECH CO., Ltd | Use of flavonoids in manufacturing compositions for wound healing |
WO2017077445A1 (en) | 2015-11-02 | 2017-05-11 | Novartis Ag | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor |
WO2018060833A1 (en) | 2016-09-27 | 2018-04-05 | Novartis Ag | Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib |
CN111374971A (zh) * | 2020-04-26 | 2020-07-07 | 南开大学 | 香叶木素在制备用于治疗炎症性肠病的药物中的应用 |
CN111454240B (zh) * | 2020-04-30 | 2023-05-16 | 上海爱启医药技术有限公司 | 制备二硒醚化合物的方法 |
CN115197190A (zh) * | 2021-04-09 | 2022-10-18 | 中国海洋大学 | 一种新型植物黄酮衍生物及其制备方法和应用 |
CN115197191A (zh) * | 2021-04-09 | 2022-10-18 | 中国海洋大学 | 一种新型中药黄酮衍生物及其制备方法和应用 |
KR102356603B1 (ko) | 2021-08-05 | 2022-02-08 | 지엘팜텍주식회사 | 안구건조증 치료를 위한 레코플라본 함유 점안 조성물 |
KR102583151B1 (ko) | 2021-08-05 | 2023-09-26 | 지엘팜텍주식회사 | 안구건조증 치료를 위한 레코플라본 함유 점안 조성물 및 이의 제조방법 |
WO2023014117A1 (ko) | 2021-08-05 | 2023-02-09 | 지엘팜텍주식회사 | 안구건조증 치료를 위한 레코플라본 함유 점안 조성물 및 이의 제조방법 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0617304B2 (ja) * | 1982-09-09 | 1994-03-09 | 理化学研究所 | 制癌剤 |
JPS6025923A (ja) * | 1983-07-22 | 1985-02-08 | Otsuka Pharmaceut Co Ltd | 5−リポキシゲナ−ゼ阻害剤 |
JPS60100570A (ja) * | 1983-11-07 | 1985-06-04 | Otsuka Pharmaceut Co Ltd | 新規フラボン誘導体 |
KR890700117A (ko) * | 1986-12-12 | 1989-03-02 | 쓰무라 아끼라 | 유효성분으로서 칼콘 유도체를 함유하는 항 궤양제 및 신규의 칼콘 유도체 |
US5278174A (en) * | 1990-06-04 | 1994-01-11 | Scios Nova, Inc. | Sigma binding site agents |
IT1245371B (it) * | 1991-03-28 | 1994-09-20 | Geymonat Spa | Derivati di flavoni, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono |
US5399584A (en) * | 1992-05-05 | 1995-03-21 | The Procter & Gamble Company | Use of flavone derivatives for gastroprotection |
JPH0725761A (ja) * | 1993-07-09 | 1995-01-27 | Kureha Chem Ind Co Ltd | 軟骨保護剤 |
-
1996
- 1996-07-25 KR KR1019960030494A patent/KR100447918B1/ko not_active IP Right Cessation
-
1997
- 1997-07-25 US US09/214,889 patent/US6025387A/en not_active Expired - Lifetime
- 1997-07-25 WO PCT/KR1997/000144 patent/WO1998004541A1/en active IP Right Grant
- 1997-07-25 DE DE69715216T patent/DE69715216T2/de not_active Expired - Lifetime
- 1997-07-25 EP EP97932032A patent/EP0915864B1/en not_active Expired - Lifetime
- 1997-07-25 JP JP50871298A patent/JP3377214B2/ja not_active Expired - Fee Related
- 1997-07-25 CA CA002261267A patent/CA2261267C/en not_active Expired - Fee Related
- 1997-07-25 DK DK97932032T patent/DK0915864T3/da active
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001181190A (ja) * | 1999-12-22 | 2001-07-03 | Takeda Chem Ind Ltd | 医薬組成物 |
JP2006509720A (ja) * | 2002-05-17 | 2006-03-23 | メルクル・ゲーエムベーハー | 潰瘍治療用プロトンポンプ阻害剤としての環付加ピロール化合物 |
JP2007504217A (ja) * | 2003-09-04 | 2007-03-01 | ドン・ア・ファーム・カンパニー・リミテッド | 7−カルボキシメチルオキシ−3’,4’,5−トリメトキシフラボン一水和物、その製造方法及び用途 |
WO2006011669A1 (ja) * | 2004-07-28 | 2006-02-02 | Santen Pharmaceutical Co., Ltd. | 新規桂皮酸関連化合物 |
JP2009527461A (ja) * | 2006-01-09 | 2009-07-30 | カウンシル オブ サイエンティフィック アンド インダストリアル リサーチ | 胃腸毒性、関連する症状及び潰瘍の処置のための天然作用物質 |
JP2010529112A (ja) * | 2007-06-07 | 2010-08-26 | ドン・ア・ファーム・カンパニー・リミテッド | 粘液分泌の刺激剤としての3’,4’,5−トリメトキシフラボン誘導体、その方法、および上記化合物を含んでなる医薬組成物 |
JP2012116785A (ja) * | 2010-11-30 | 2012-06-21 | Tsumura & Co | 5,7‐ジヒドロキシ‐6‐メトキシフラボン類の製造方法 |
Also Published As
Publication number | Publication date |
---|---|
DK0915864T3 (da) | 2002-12-30 |
US6025387A (en) | 2000-02-15 |
WO1998004541A1 (en) | 1998-02-05 |
DE69715216D1 (de) | 2002-10-10 |
DE69715216T2 (de) | 2003-05-08 |
JP3377214B2 (ja) | 2003-02-17 |
EP0915864B1 (en) | 2002-09-04 |
KR100447918B1 (ko) | 2005-09-28 |
CA2261267C (en) | 2003-10-07 |
CA2261267A1 (en) | 1998-02-05 |
EP0915864A1 (en) | 1999-05-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11514015A (ja) | 胃腸管保護作用により炎症性腸疾病で治癒効果を有するフラボン及びフラバノン化合物 | |
FI87207B (fi) | Foerfarande foer framstaellning av nya, terapeutiskt anvaendbara 4-acetyl-3-hydroxifenoxi-(laegre alkyl)-3,4 -dihydro-2h-1-bensopyranderivat. | |
US5280024A (en) | Medicinal use of 3',5'-di-tert.-butyl-4'-hydroxy flavones | |
NO172343B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive askorbinsyrederivater | |
WO1997044306A1 (fr) | Derives de chalcone et medicaments les contenant | |
JP2010143937A (ja) | 抗凝血薬として用いるクマリン誘導体 | |
NZ575902A (en) | Diosmetin derivative compounds, a process for their preparation and their use in the treatment of chronic venous disease | |
EP0902022B1 (en) | Novel benzofuranone derivatives and process for producing the same | |
US5399584A (en) | Use of flavone derivatives for gastroprotection | |
RU2266291C2 (ru) | Халконовые кумарины | |
US6965039B2 (en) | 7-carboxy-flavone derivatives preparation method and therapeutic use | |
RU2302416C2 (ru) | Моногидрат 7-карбоксиметилокси-3',4' 5-триметоксифлавона, способ его получения и применения | |
RU2252938C2 (ru) | Халконы и фармацевтическая композиция на их основе | |
KR100521839B1 (ko) | 신규 플라본 유도체, 약학적으로 허용가능한 그의 염 및그를 포함하는 약학적 조성물 | |
KR100857841B1 (ko) | 벤조피란 유도체 및 항알레르기제 | |
US5173498A (en) | Substituted 3-thia- and 3-oxa-alkylflavones, a process for their preparation, the use thereof, medicaments based on these compounds and intermediates | |
Maddi | Synthesis and anti-inflammatory activity of Phenylalanine analogs | |
WO1993019066A1 (en) | Imidazopyridine derivative and medicine | |
KR100868702B1 (ko) | 바이플라보노이드 유도체를 함유하는 항염증, 항알러지용조성물 | |
JP2003081827A (ja) | ベンゾピラン誘導体及び抗アレルギー剤 | |
WO2009110008A1 (en) | Anti-ulcer activity of flavone analogs | |
JPH0433785B2 (ja) | ||
HU194816B (en) | Process for producing 1-/2-hydroxy-aryl/-1-alkanon-oxim derivatives and pharmaceutical compositions containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20071206 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20081206 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20091206 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101206 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101206 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111206 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111206 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121206 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121206 Year of fee payment: 10 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131206 Year of fee payment: 11 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |